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Working Group (http://www.cebm.net/levels_of_evidence.asp). 
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database of evidence-based questions and answers is copyrighted by FPIN. If you are interested 
in submitting questions to be answered or writing answers for this series, go to 
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Clinical Question 
How should patients with subclinical hypothyroidism be managed? 
Evidence-Based Answer 
Treatment of subclinical hypothyroidism with levothyroxine may be of most benefit to patients 
with symptoms suggestive of hypothyroidism and those patients with thyroid-stimulating 
hormone (TSH) levels higher than 10 µIU per mL (10 mIU per L) or positive anti-thyroid 
peroxidase (TPO) antibodies. Levothyroxine is recommended for pregnant patients. For 
asymptomatic patients with TSH levels between 4.5 and 10 µIU per mL (4.5 and 10 mIU per L), 
treatment may not be beneficial, but their thyroid function should be monitored at six- to 12-
month intervals. [Strength of recommendation: C, based on expert opinion and systematic 
reviews with troublesome heterogeneity of disease-oriented evidence] 
Evidence Summary 
Subclinical hypothyroidism is a laboratory diagnosis that refers to a patient with an elevated TSH 
level and a normal free thyroxine (FT4) level. About 2 to 5 percent of these patients each year 
will develop overt hypothyroidism,1-3 but the benefits of detecting and treating the subclinical 
disease are not well established. 
A recent scientific review1 recognized the paucity of randomized controlled trials on the subject, 
with scant data related to clinical outcomes such as cardiac dysfunction and neuropsychiatric 
symptoms. Most studies separated patients into two groups. For patients with a TSH level 
between 4.5 and 10 µIU per mL, evidence regarding benefits of treatment was insufficient or 
absent. Patients with a TSH level higher than 10 µIU per mL but a normal FT4 level had a higher 
risk of developing overt hypothyroidism, but evidence that treatment with thyroid hormone 
replacement would improve patient-oriented outcomes (i.e., morbidity, mortality, and symptom 
improvement) was inconclusive. Similarly, the presence of anti-TPO antibodies predicted a 
higher risk of developing overt disease, but the evidence was insufficient to recommend routine 
measurement of anti-TPO antibodies. 
Other reviews show inconclusive results,4,5 and many studies lack clinical relevance because of 
their focus on disease-oriented or physiologic outcomes.3 Some studies that show improvement 
in patient-oriented outcomes included patients that were already being treated for thyroid 
disorders, and therefore these results cannot be applied to the general population. 
There are no published trials assessing the benefits of levothyroxine in pregnant women with 
subclinical hypothyroidism, but the potential benefits of treatment for a thyroid-hormone-
deficient mother and fetus, compared to the risks of treatment for an euthyroid mother and fetus, 
justifies its use.1 
Recommendations from Others 
One expert panel recommends that TSH levels between 4.5 and 10 µIU per mL should not be 
routinely treated, but patients with these levels should have thyroid function tests repeated at six- 
to 12-month intervals.1 Patients with symptoms of hypothyroidism may benefit from a trial of 
levothyroxine while monitoring symptomatic improvement, although distinguishing a true 
therapeutic effect from placebo effect may be difficult.  
The American Association of Clinical Endocrinologists recommends levothyroxine therapy for 
patients with TSH levels higher than 10 µIU per mL, positive anti-TPO antibodies, or goiter; the 
recommended starting dose of 25 to 50 mcg daily must be adjusted as necessary after repeating 
the TSH level in six to eight weeks.2 Annual evaluation of TSH is appropriate after a level 
between 0.3 and 3.0 µIU per mL (0.3 and 
3.0 mIU per L) is achieved. 
Clinical Commentary 
Subclinical hypothyroidism often is diagnosed when thyroid tests are ordered for nonspecific 
symptoms such as depression, weight gain, or fatigue. The physician must then decide if the 
patient's symptoms are caused by a relative thyroid hormone deficiency, and whether thyroid 
hormone replacement would improve the patient's well-being. Lacking clear-cut evidence to 
guide these decisions, the physician's role is to discuss the uncertain implications of the diagnosis 
and the potential risks (such as osteoporosis and impaired myocardial contractility) and benefits 
of levothyroxine therapy to allow a patient to make an informed decision about therapy. 
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